James (Josh) Wilson Faruqi & Faruqi, LLP
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Edwards Lifesciences Corporation
30 oct. 2024 21h10 HE | Faruqi & Faruqi LLP
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Edwards To Contact Him Directly To Discuss Their Options If...
James (Josh) Wilson Faruqi & Faruqi, LLP
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Metagenomi
30 oct. 2024 21h09 HE | Faruqi & Faruqi LLP
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Metagenomi To Contact Him Directly To Discuss Their Options If...
James (Josh) Wilson Faruqi & Faruqi, LLP
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Paragon 28
30 oct. 2024 20h42 HE | Faruqi & Faruqi LLP
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Paragon 28 To Contact Him Directly To Discuss Their Options ...
James (Josh) Wilson Faruqi & Faruqi, LLP
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Elanco Animal Health
30 oct. 2024 17h46 HE | Faruqi & Faruqi LLP
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Elanco To Contact Him Directly To Discuss Their Options ...
greylogo.png
VitalHub Announces Acquisition of Strata Health
30 oct. 2024 16h30 HE | VitalHub Corp.
TORONTO, Oct. 30, 2024 (GLOBE NEWSWIRE) -- VitalHub Corp. (TSX: VHI) (OTCQX: VHIBF) (the “Company” or “VitalHub”) is pleased to announce that it has acquired (the “Acquisition”) Strata Health...
Logo Long.png
Numab Therapeutics Announces Initiation of Phase 1 Clinical Study of NM32 Program in Patients with Solid Tumors
30 oct. 2024 08h00 HE | Numab Therapeutics AG
NM32 is a first-in-class half-life-enhanced T-cell engager targeting ROR1, a tumor associated antigen with broad expression in solid tumors and hematological malignancies Low molecular...
Doctor 5
KFSHRC Leading Healthcare Innovation and Transformation in Saudi Arabia KFSHRC Leading Healthcare Innovation and Transformation in Saudi Arabia
Lynch Carpenter Logo-01.png
Lynch Carpenter Investigates Claims in ATSG Data Breach
29 oct. 2024 13h03 HE | Lynch Carpenter
PITTSBURGH, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Lynch Carpenter, LLP is investigating a class action against ATSG, Inc. regarding a recently announced data breach. The ATSG data breach may have...
Regenerative Medical Solutions Logo.png
RMS Sponsors the 5th Summit on Stem Cell Derived Islets
29 oct. 2024 09h00 HE | Regenerative Medical Solutions
Boston, MA, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Regenerative Medical Solutions (RMS) is sponsoring the 5th Summit on Stem Cell Derived Islets, which will be held on October 28-29 at the Joseph B....
Captura de pantalla 2023-11-10 082355 big.png
Lipella Pharmaceuticals to Present at 2024 Spartan Capital Investor Conference
29 oct. 2024 08h30 HE | Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals to Present at 2024 Spartan Capital Investor Conference